Indications
Open Access TIMES Journals
Login
Register
Login
Register
Indications
Oncology · Hematology
Spine Surgery
Cardiovascular
Diabetes + Endocrinology
Pneumology
Ophthalmology
Gynecology · Urology
Dermatology · Immunology · Rheumatology
Neurology · Psychiatry
Gastroenterology
Infectiology · Anesthesiology · Pain
Primary Care
Open Access TIMES Journals
Oncology · Hematology
Spine Surgery
Cardiovascular
Diabetes + Endocrinology
Pneumology
Ophthalmology
Gynecology · Urology
Dermatology · Immunology · Rheumatology
Neurology · Psychiatry
Gastroenterology
Infectiology · Anesthesiology · Pain
Primary Care
Oncology · Hematology
Case Reports
Expert Opinions
Congress News
E-Learning
Webinar
Faculty
healthbook TIMES
Homepage
>
Oncology · Hematology
>
Articles
ARASAFE: Lower docetaxel dose improves safety in patients with mHSPC
Genitourinary Cancer
Share:
ESMO 2025
Related content
Genitourinary Cancer
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
Eur J Cancer
Tombal B, Hussain M, Saad F, Fizazi K, Shore N, Kopyltsov E, Bögemann M, Mendez-Vidal MJ, Littleton N, Srinivasan S, Verholen F, Smith MR
doi: 10.1016/j.ejca.2026.116730
Myelodysplastic syndromes
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study
Haematologica
Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Díez-Campelo M, Oliva EN
doi: 10.3324/haematol.2025.288956
APCCC 2026
Genitourinary Cancer
Triplet Therapy in mHSPC: Patient Selection and Treatment Intensification
Further Publications
The safety of extended dosing pembrolizumab when compared to traditional dosing: A review and meta-analysis of retrospective studies
Lung Cancer
Sekar P, Ashok Kumar A, Hughes I, Mason R, Dzienis M
doi: 10.1016/j.lungcan.2025.108585
RECOMMENDED
Further Publications
Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Trials
★ 2
Recommended by Dr Andreas Müller, Faculty Member
Am J Hematol
Mahmoud A, Eltaher B, Shah P, Vengilote R, Mostafa M, Afzal A, Sanfilippo KM
doi: 10.1002/ajh.70090
Leukemia
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia
Br J Haematol
Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A
doi: 10.1111/bjh.70380
SABCS 2025
Breast Cancer
DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer
Multiple Myeloma (MM)
Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis
®
)-Based Regimens in Patients with NDMM
ESMO 2025
Genitourinary Cancer
CAPItello-281: Capivasertib plus abiraterone and ADT improves rPFS in
PTEN
-deficient mHSPC